SCHEMBL10074997

SCHEMBL10074997

CC(C)(CNC(=O)CC(Cc1cc(F)ccc1F)NC(=O)OCc1ccccc1)CNC(=O)[C@@H](O)[C@@H](COCc1ccccc1)NC(=O)OCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB1 P20618 2/20 0.38
SYK P43405 1/20 0.37
CTSS P25774 6/20 0.37
TRPM8 Q7Z2W7 1/20 0.36
CTRB1 P17538 2/20 0.36
CTSL P07711 4/20 0.35
CTSB P07858 2/20 0.35
KLK5 Q9Y337 1/20 0.35
CTSK P43235 2/20 0.35
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
PSMB11 A5LHX3 1/20 0.34
PSMA7 O14818 1/20 0.34
PSMA1 P25786 1/20 0.34
PSMA2 P25787 1/20 0.34
PSMA3 P25788 1/20 0.34
PSMA4 P25789 1/20 0.34
PSMB8 P28062 1/20 0.34
PSMB9 P28065 1/20 0.34
PSMA5 P28066 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10074153 1.00 PSMB1 (0.38) PSMB1SYKCTSSTRPM8CTRB1
SCHEMBL10074727 0.96 SYK (0.42) PSMB1SYKCTSSKLK5CTSK
SCHEMBL10078394 0.96 SYK (0.42) PSMB1SYKCTSSKLK5CTSK
SCHEMBL10074252 0.96 SYK (0.42) PSMB1SYKCTSSKLK5CTSK
SCHEMBL10077059 0.95 CTSS (0.39) PSMB1SYKCTSSCTSBKLK5
SCHEMBL10077385 0.95 CTSS (0.39) PSMB1SYKCTSSCTSBKLK5
SCHEMBL10074726 0.95 CTSS (0.39) PSMB1SYKCTSSCTSBKLK5
SCHEMBL10078263 0.95 CTSS (0.35) PSMB1CTSSCTSLCTSBKLK5
SCHEMBL10074460 0.93 CTSS (0.42) SYKCTSSKLK5CTSKREN
SCHEMBL10074141 0.93 CTSS (0.42) SYKCTSSKLK5CTSKREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2418196-A1 Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors IMTM GmbH (DE) 2012-02-15 EP disclosed
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS IMTM GMBH (DE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS SERPINB1, CMA1, CPA3 PSMB1 555/4885SYK 2686/4885CTSS 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.